| Literature DB >> 31581590 |
Atteneri López-Arencibia1,2, Desirée San Nicolás-Hernández3, Carlos J Bethencourt-Estrella4, Ines Sifaoui5, María Reyes-Batlle6, Rubén L Rodríguez-Expósito7, Aitor Rizo-Liendo8, Jacob Lorenzo-Morales9,10, Isabel L Bazzocchi11, José E Piñero12,13, Ignacio A Jiménez14.
Abstract
Leishmaniasis and American trypanosomiasis are parasitic diseases that cause significant clinical, social and economic impact on the population of tropical and subtropical countries. Their current treatment is limited and presents multiple drawbacks, including high toxicity, high cost, lengthy treatment plans, as well as the emergence of resistant species. Therefore, there is a need to find new lead compounds with high potency against parasites and low toxicity in patients. In the present work, the bioguided fractionation of an endemic plant from the Canary Islands, Withania aristata, led to the identification of withanolide-type metabolites (1-3) with leishmanicidal and trypanocidal activities. Compounds 1 and 3 showed a significant dose-dependent inhibition effect on the proliferation of L. amazonensis promastigotes and T. cruzi epimastigotes, higher than the reference drugs, miltefosine and benznidazole, respectively. Moreover, compounds 1-3 were more potent (IC50 0.055-0.663 µM) than the reference drug against the intracellular amastigote stage of L. amazonensis, with a high selectivity index on murine macrophage cells (SI 58.66-216.73). Studies on the mechanism of death showed that the compounds induced programmed cell death or that which was apoptosis-like. The present findings underline the potential of withanolides as novel therapeutic antikinetoplastid agents.Entities:
Keywords: Leishmania; Trypanosoma; Withania aristata; apoptosis-like; withanolides
Year: 2019 PMID: 31581590 PMCID: PMC6963971 DOI: 10.3390/pathogens8040172
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Activity a against promastigote stage of Leishmania spp., epimastigote stage of T. cruzi, and cytotoxicity against eucariotic cells of the extract, fractions and sub-fractions from Withania aristata leaves.
| Extract/Fractions | Murine Macrophages CC50 c (µg/mL) | |||
|---|---|---|---|---|
| Acetone extract | 2.87 | 20.25 | 12.78 | 42.63 |
| Fraction 1 | 12.27 | 19.12 | 28.91 | 81.39 |
| Fraction 2 | 1.02 | 12.73 | 1.12 | 11.22 |
| F2A | 1.37 | >50 | 11.24 | 13.79 |
| F2B | 1.05 | 3.06 | 1.93 | 8.02 |
| F2C | 1.40 | 4.21 | 3.14 | 10.23 |
| F2D | 0.36 | 1.85 | 1.73 | 7.65 |
| F2E | 0.19 | 2.70 | 2.02 | 13.90 |
| F2F | 2.11 | >50 | 5.74 | 21.12 |
| Fraction 3 | 4.53 | 22.28 | 3.63 | 46.11 |
| F3A | 2.51 | 9.03 | 8.42 | 22.90 |
| F3B | 2.48 | 5.96 | 6.04 | 23.78 |
| F3C | 2.35 | >50 | 5.56 | 16.08 |
| F3D | 1.01 | 3.67 | 3.59 | 9.56 |
| F3E | 3.42 | >50 | 7.05 | 21.57 |
| F3F | 19.52 | >50 | >50 | 43.98 |
| Miltefosine d | 2.64 | 1.35 | 29.42 | |
| Benznidazole d | 1.81 | 104.1 |
a Sub-fraction not included (F2G) in the table was inactive (IC50 > 50 µg/mL) against the three parasite species. b IC50: concentration able to inhibit 50% of the cells. c CC50: concentration able to reduce the cell viability by 50%. d Drugs used as the positive controls.
Scheme 1Flowchart of the kinetoplasticidal bioguided fractionation of Withania aristata leaves.
Figure 1Chemical structure of withanolides 1–3 isolated from Withania aristata.
Activity of withanolides 1–3 against the promastigote stage of Leishmania, epimastigote stage of T. cruzi and cytotoxicity against eucariotic cells.
| Cp | SI | SI | SI c | Murine Macrophages CC50 (µM) b | |||
|---|---|---|---|---|---|---|---|
|
| 0.83 ± 0.07 | 14.36 | 13.22 ± 1.16 | 0.91 | 1.02 ± 0.10 | 11.69 | 11.92 ± 1.08 |
|
| 27.37 ± 1.03 | 3.12 | >50 | 14.68 ± 0.43 | 5.82 | 85.47 ± 6.00 | |
|
| 2.82 ± 0.07 | 4.35 | 20.88 ± 1.33 | 0.59 | 2.41 ± 0.11 | 5.09 | 12.26 ± 1.16 |
| M d | 6.48 ± 0.10 | 11.14 | 3.31 ± 0.11 | 21.81 | 72.18 ± 1.25 | ||
| B d | 6.95 ± 0.50 | 57.54 | 399.91 ± 1.04 |
a IC50: concentration able to inhibit 50% of parasites, expressed as µM ± standard deviation (SD). b CC50 concentration able to inhibit 50% of murine macrophages, expressed as µM ± standard deviation (SD). c SI: selectivity index (CC50/IC50). d M: miltefosine, B: benznidazole were used as the positive controls. Cp: Compounds.
Activity of withanolides 1–3 against amastigote of L. amazonensis.
| Compound | SI a | |
|---|---|---|
|
| 0.055 ± 0.009 | 216.73 |
|
| 0.663 ± 0.075 | 128.91 |
|
| 0.209 ± 0.028 | 58.66 |
| Miltefosine | 3.12 ± 0.12 | 23.13 |
a SI: selectivity index (CC50/IC50).
Figure 2Changes in the mitochondrial membrane potential (ΔΨm) after 24 h of incubation with the IC90 of withanolides 1–3 in (A) L. amazonensis and (B) T. cruzi. C-: Control. Error bars represent the standard deviation (SD). Each data point indicates the mean of the results of three measurements (***) p < 0.001.
Figure 3ATP levels in relative luminescence units of (A) L. amazonensis and (B) T. cruzi after 24 h of incubation with the IC90 of compounds 1–3. C-: Control. Error bars represent the standard deviation (SD). Each data point indicates the mean of the results of three measurements (**) p < 0.01.
Figure 4Hoechst-propidium iodide staining: L. amazonensis incubated with IC90 of withanolides 1–3 and the chromatin condensation was analyzed after 24 h. Images (100×) show chromatin condensation (blue) in treated cells. Red fluorescence corresponds to the propidium iodide stain. C-: Control. Images were obtained using an EVOS FL Cell Imaging System.
Figure 5Plasma membrane permeability alteration (Sytox® Green) caused by withanolides 1–3. C-: Control. Images (100×) are representative of the cell population observed in the performed experiments. Images were obtained using an EVOS FL Cell Imaging System.
Figure 6CellROX Deep Red staining. Results after 24 h of incubation of L. amazonensis promastigotes with the IC90 of withanolides 1–3. C-: Control. Images were captured using an EVOS FL Cell Imaging system (Thermo Fisher Scientific, Waltham, MA, USA) (100×).